Key trials that will affect the therapy landscape for NSCLC
Characterizing a phenomenon in GBM patients who do not respond well to immunotherapy
Using checkpoint inhibitors at earlier stages of bladder cancer – the next step in immunotherapy?
The rarer toxicities of immunotherapy
Abstracts presented at ASCO 2017: drug re-challenge and pharmacoeconomics